Pfizer’s Maraviroc Not Ready For Personalized Approach – Advisory Cmte.
Executive Summary
FDA's Antiviral Drugs Advisory Committee is concerned about optimal dosing for Pfizer's HIV therapy maraviroc because the CCR5 co-receptor antagonist may have a narrow therapeutic window